论文部分内容阅读
目的探讨白细胞介素17(IL-17)和转化生长因子β1(TGF-β1)在结直肠癌中的表达,为临床诊断和治疗提供参考。方法将2013年2月至2014年6月110例手术治疗的结直肠癌患者,根据术后肿瘤是否发生转移分为两组,A组60例为无转移患者,其中结肠癌患者24例为A1组,直肠癌患者36例为A2组;B组50例为术后发生转移的患者,其中结肠癌患者26例为B1组,直肠癌患者24例为B2组;另选50例健康体检者作为对照组(C组)。检测3组患者血清IL-17和TGF-β1水平,其中A组患者分别检测术前、术后血清IL-17和TGF-β1水平。结果 A组术前、B组血清IL-17水平均明显高于C组(P均<0.01);A组术前、术后血清IL-17水平均明显低于B组(P均<0.01);A组术后血清IL-17水平比术前明显下降(P<0.05),与C组比较无统计学差异(P>0.05)。A组术前、术后血清TGF-β1水平比较无统计学差异(P>0.05),与C组比较亦无统计学差异(P>0.05);B组血清TGF-β1水平明显高于A组术前、术后以及C组(P均<0.01)。A、B两组中结肠癌与直肠癌患者血清IL-17和TGF-β1水平比较差异均无统计学意义(P均>0.05)。结论血清IL-17、TGF-β1水平随着结直肠癌发展而升高,与结直肠癌的发生、发展和转移密切相关,检测其水平对早期诊断与疗效评价有一定价值。
Objective To investigate the expression of interleukin-17 (IL-17) and transforming growth factor-β1 (TGF-β1) in colorectal cancer and provide reference for clinical diagnosis and treatment. Methods One hundred and ten patients with colorectal cancer undergoing surgery from February 2013 to June 2014 were divided into two groups according to whether tumor metastasis occurred or not. A group of 60 patients without metastasis, of which 24 patients with colon cancer were A1 36 patients with rectal cancer were Group A2, 50 patients in Group B were patients with postoperative metastasis, 26 patients with colon cancer were Group B1, 24 patients with rectal cancer were Group B2, and 50 patients were selected as healthy subjects Control group (C group). Serum levels of IL-17 and TGF-β1 were detected in three groups. Patients in group A were measured serum IL-17 and TGF-β1 levels before and after surgery respectively. Results The levels of serum IL-17 in group A before operation and in group B were significantly higher than those in group C (all P <0.01). The levels of IL-17 in group A before and after operation were significantly lower than those in group B (all P <0.01) The level of IL-17 in group A was significantly lower than that before operation (P <0.05), but there was no significant difference between group A and C (P> 0.05). There was no significant difference in serum TGF-β1 level between group A and group C (P> 0.05), but there was no significant difference between group A and group C (P> 0.05). The level of TGF-β1 in group B was significantly higher than that of group A Preoperative, postoperative and C group (P <0.01). The serum levels of IL-17 and TGF-β1 in patients with colon cancer and rectal cancer in groups A and B had no significant difference (all P> 0.05). Conclusions Serum levels of IL-17 and TGF-β1 are increased with the development of colorectal cancer. They are closely related to the occurrence, development and metastasis of colorectal cancer. The detection of serum IL-17 and TGF-β1 levels has some value in early diagnosis and therapeutic evaluation.